What medical device teams need now: agility
The medtech industry is facing three top challenges. Becoming more nimble can help navigate them.
Medical device R&D looks to increase efficiency and control costs
Amid increasing demand for value-based care, medtech companies find opportunities with virtual engagement.
Healthcare business intelligence applications
Business intelligence can provide valuable insight that uncovers trends and breakthroughs that are key to successful life science operations.
How artificial intelligence is impacting clinical trials
Artificial intelligence has remarkable potential for all aspects of life science operations, including revolutionizing the way new treatments, drugs, and devices are tested and evaluated.
Medical device is moving toward an insights-first approach
The pandemic’s lasting legacy for medical device teams will be building on the lessons learned from virtual engagement and working toward a more holistic insights management strategy.
Within3 on the MAPS Elevate Podcast: Engage stakeholders to get more actionable insights
Time with your KOLs and medical affairs program stakeholders is precious. How can you make the most of it?
How artificial intelligence is changing drug development
Drug development is outrageously expensive and time-consuming. Learn how artificial intelligence is finding efficiencies, saving costs, and improving patient outcomes.
Video: What is a DOL? How can I find and engage them?
Life science teams are increasingly seeking out digital opinion leaders – what value do these experts offer, and how can you identify them?
How to run a successful virtual conference for medical events
The life science industry relies heavily on a steady stream of information and interaction between various health care professionals, including medical affairs teams, HCPs, and health tech teams.
Digital health tools changed patient expectations – and life science is responding
The pandemic gave telehealth and other digital health tools a massive boost. Here’s how patient behaviors will continue to affect how pharma and medical device companies use technology to gain patient and HCP insights.